Bridget F. Koontz

Dr. Bridget Koontz trained at Harvard Medical School, University of North Carolina-Chapel Hill, and Duke University School of Medicine, where she was on faculty at the Duke Cancer Institute from 2007 to 2021. She is now leading the US oncology network for GenesisCare, a leading global oncology network and research organization.

Her interests are in promoting excellence of clinical care for patients with genitourinary malignancies, and clinical and translational research to improve both the treatment of and recovery from cancer. She has frequently been faculty at ASTRO and ASCO GU meetings, and has published over 100 articles, chapters, and books, including acting as editor of the practical handbook Radiation Therapy Treatment Effects: An Evidence-Based Guide to Managing Toxicity (2017).

Dr. Koontz’s current research is to improve the effectiveness of prostate cancer radiotherapy and reducing the toxicities of such care. She has conducted translational laboratory research developing models of radiation-induced pelvic toxicity, has led phase I and phase II trials in prostate cancer, and is the national PI of NRG-GU011, a trial of stereotactic radiotherapy for oligometastatic prostate cancer.

She continues to investigate clinical efforts to improve the quality of life of cancer survivors through technology such as eHealth apps and activity trackers. She currently represents radiation oncology as a member of the NCI’s Genitourinary Steering Committee for NCTN trials.